Advertisement
BSX vs MDT
Which Stock Would AI Choose? Boston Scientific (BSX) vs. Medtronic (MDT) Stock Comparison
Key Takeaways
- BSX has undergone a sharp de-rating over the trailing twelve months, with the stock down more than 50% amid headwinds in key cardiac franchises and multiple product recalls.
- MDT is delivering its strongest revenue growth in a decade and has raised guidance, yet its shares remain range-bound and well below prior highs.
- The two companies diverge on momentum: BSX faces near-term growth and quality scrutiny, while MDT offers steadier, more diversified fundamentals.
- Valuation, dividend income, and volatility are the key contrasts: MDT trades at a lower forward multiple with a ~3.2% yield and low beta, while BSX trades near its historical valuation floor.
- Both stocks are exposed to the competitive electrophysiology (heart rhythm) market, where pulsed field ablation is reshaping share dynamics.
Introduction
Boston Scientific Corporation and Medtronic plc are two of the largest names in medical technology, competing directly in cardiology, cardiac rhythm management, and electrophysiology (EP, the treatment of heart-rhythm disorders). A stock comparison between BSX and MDT is especially relevant today because the two companies are moving in different directions: one is absorbing a growth slowdown and product-quality issues, while the other is rebuilding momentum after years of sluggish performance. Growth-oriented investors, dividend-focused investors, and traders monitoring relative performance and market positioning will find the contrast useful for understanding how sentiment is shifting across the medtech sector.
BSX Overview and Recent Performance
Boston Scientific is a diversified medical device maker with leadership positions in interventional cardiology, cardiac rhythm management, urology, neuromodulation, and endoscopy. The company is also a front-runner in pulsed field ablation (PFA), a newer catheter-based technology for treating atrial fibrillation, through its FARAPULSE and WATCHMAN franchises. In recent quarters, BSX reported solid headline results—including first-quarter revenue of roughly $5.2 billion—but cut its full-year outlook as three businesses came under pressure: WATCHMAN (a left atrial appendage closure device), electrophysiology, and urology.
Competitive share losses in U.S. electrophysiology, softer standalone WATCHMAN procedure volumes, and a series of Class II recalls have weighed on sentiment. The company responded with a multi-year restructuring plan targeting about $500 million in annual savings by 2029 and raised its sales-growth outlook after a second-quarter beat. Even so, shares have declined more than 50% over the trailing twelve months, and forward earnings estimates have trended lower. Longer-term catalysts—including new product launches and the pending Penumbra acquisition—have not yet restored investor confidence.
MDT Overview and Recent Performance
Medtronic, headquartered in Dublin, Ireland, is the world's largest pure-play medical technology company, spanning cardiovascular care, neuroscience, medical-surgical products, and (until its recent separation) diabetes. In its fiscal 2026 year, MDT generated roughly $36.4 billion in revenue, its highest annual revenue growth in ten years, driven by accelerating growth in Cardiac Ablation Solutions—where revenue rose about 78%—and a strong pulsed field ablation portfolio built around its Sphere-9 and Affera systems.
Management has also executed a portfolio reshaping strategy, completing the initial public offering (IPO) of its MiniMed diabetes business while retaining a majority stake, and pursuing targeted acquisitions such as CathWorks, Scientia Vascular, and SPR Therapeutics. For fiscal 2027, the company raised its organic revenue growth guidance to a range of 7.25% to 7.75% and its adjusted earnings per share (EPS) outlook. Despite this improving fundamental picture, MDT shares have slipped more than 7% in 2026 and remain below levels seen five years ago, in part reflecting a low-growth reputation and a widely reported cybersecurity incident earlier in the year.
Trending AI Robots
For traders who want a data-driven read on relative positioning like this BSX versus MDT comparison, Tickeron's Trending AI Robots page offers a curated view of the platform's top-performing automated strategies. Tickeron operates hundreds of AI trading bots that collectively trade thousands of tickers across different timeframes, but only a small selection—roughly 25 of more than 350 available bots—earns a place in this section based on their suitability for current market conditions. These bots vary widely in trading style, strategy, timeframe, win rate, profit factor, and average trade duration, with some featured strategies posting annualized returns above 100%. Each bot publishes its own closed-trade history and risk metrics. Explore the Trending AI Robots page to see which automated strategies are currently best aligned with the market.
Head-to-Head Comparison
Although both companies compete in overlapping markets, their risk and return profiles differ sharply. MDT is the larger and more diversified enterprise, with a defensive, lower-volatility profile—its stock carries a beta of roughly 0.5, meaning it tends to move about half as much as the broader market. It also pays a dependable dividend, having raised its payout for 49 consecutive years, and trades near 15 times forward earnings. BSX, by contrast, has historically commanded a premium valuation for faster growth but now trades near a forward multiple of roughly 14 times after its sell-off, as its premium compressed.
On momentum, the picture is inverted. MDT is showing improving operational momentum, with broad-based segment growth and raised guidance, even though its stock has lagged. BSX retains a strong innovation pipeline but is currently managing share erosion in electrophysiology, a WATCHMAN slowdown, and recall-related scrutiny, which have driven a prolonged decline in relative performance. Risk factors also differ: BSX faces integration and execution risk around the Penumbra acquisition, while MDT carries exposure to tariffs, cybersecurity concerns, and slower-growing legacy franchises.
Tickeron AI Verdict
Based on observable factors such as trend consistency, stability, and relative positioning, Tickeron's AI would likely tilt toward MDT in the current environment. The stock offers a steadier trend profile, lower volatility, improving revenue growth, and raised guidance, which together suggest more favorable risk-adjusted positioning than BSX, whose negative momentum, guidance reductions, and quality concerns make its near-term trend harder to defend. That said, BSX's reset valuation and its 2027–2028 product pipeline could support a longer-horizon recovery, so the AI's preference is better read as probabilistic and condition-dependent rather than a definitive conclusion. Traders should weigh trend quality and stability against each stock's distinct catalyst set.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BSX is a StrongBuy and MDT is a Buy.
Momentum Indicator for BSX turns positive, indicating new upward trend
BSX saw its Momentum Indicator move above the 0 level on October 15, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 89 similar instances where the indicator turned positive. In 54 of the 89 cases, the stock moved higher in the following days. The odds of a move higher are at 61%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where BSX's RSI Indicator exited the oversold zone, 15 of 26 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 58%.
The Moving Average Convergence Divergence (MACD) for BSX just turned positive on October 12, 2026. Looking at past instances where BSX's MACD turned positive, the stock continued to rise in 25 of 44 cases over the following month. The odds of a continued upward trend are 57%.
BSX moved above its 50-day moving average on October 22, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +2.68% 3-day Advance, the price is estimated to grow further. Considering data from situations where BSX advanced for three days, in 199 of 335 cases, the price rose further within the following month. The odds of a continued upward trend are 59%.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BSX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 54%.
BSX broke above its upper Bollinger Band on October 19, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for BSX entered a downward trend on October 14, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 55 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating steady price growth. BSX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 72 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.587) is normal, around the industry mean (2.874). P/E Ratio (17.876) is within average values for comparable stocks, (2.324). Projected Growth (PEG Ratio) (0.618) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (3.117) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 94 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 97 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BSX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
MDT sees its 50-day moving average cross bullishly above its 200-day moving average
The 50-day moving average for MDT moved above the 200-day moving average on September 17, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 12, 2026. You may want to consider a long position or call options on MDT as a result. In 53 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 62%.
The Moving Average Convergence Divergence (MACD) for MDT just turned positive on October 12, 2026. Looking at past instances where MDT's MACD turned positive, the stock continued to rise in 28 of 43 cases over the following month. The odds of a continued upward trend are 65%.
MDT moved above its 50-day moving average on October 12, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for MDT crossed bullishly above the 50-day moving average on October 16, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 59%.
Following a +2.62% 3-day Advance, the price is estimated to grow further. Considering data from situations where MDT advanced for three days, in 170 of 316 cases, the price rose further within the following month. The odds of a continued upward trend are 54%.
Bearish Trend Analysis
The 10-day RSI Indicator for MDT moved out of overbought territory on October 16, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 similar instances where the indicator moved out of overbought territory. In 14 of the 26 cases, the stock moved lower in the following days. This puts the odds of a move lower at 54%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 8 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MDT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 56%.
MDT broke above its upper Bollinger Band on October 12, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for MDT entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 30 (best 1 - 100 worst), indicating outstanding price growth. MDT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 55 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.369) is normal, around the industry mean (2.874). P/E Ratio (22.746) is within average values for comparable stocks, (2.324). Projected Growth (PEG Ratio) (1.608) is also within normal values, averaging (11.052). Dividend Yield (0.031) settles around the average of (0.009) among similar stocks. P/S Ratio (3.176) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 58 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 68 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MDT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
BSX | MDT | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 11 | 37 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 72 Overvalued | 55 Fair valued | |
PROFIT vs RISK RATING 1..100 | 97 | 100 | |
SMR RATING 1..100 | 55 | 68 | |
PRICE GROWTH RATING 1..100 | 62 | 30 | |
P/E GROWTH RATING 1..100 | 94 | 58 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
MDT's Valuation (55) in the Medical Specialties industry is in the same range as BSX (72). This means that MDT’s stock grew similarly to BSX’s over the last 12 months.
BSX's Profit vs Risk Rating (97) in the Medical Specialties industry is in the same range as MDT (100). This means that BSX’s stock grew similarly to MDT’s over the last 12 months.
BSX's SMR Rating (55) in the Medical Specialties industry is in the same range as MDT (68). This means that BSX’s stock grew similarly to MDT’s over the last 12 months.
MDT's Price Growth Rating (30) in the Medical Specialties industry is in the same range as BSX (62). This means that MDT’s stock grew similarly to BSX’s over the last 12 months.
MDT's P/E Growth Rating (58) in the Medical Specialties industry is somewhat better than the same rating for BSX (94). This means that MDT’s stock grew somewhat faster than BSX’s over the last 12 months.
| BSX | MDT | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 58% | 1 day ago 54% |
| Stochastic ODDS (%) | 1 day ago 45% | 1 day ago 42% |
| Momentum ODDS (%) | 1 day ago 61% | 1 day ago 62% |
| MACD ODDS (%) | 1 day ago 57% | 1 day ago 65% |
| TrendWeek ODDS (%) | 1 day ago 57% | 1 day ago 56% |
| TrendMonth ODDS (%) | 1 day ago 56% | 1 day ago 50% |
| Advances ODDS (%) | 3 days ago 59% | 8 days ago 54% |
| Declines ODDS (%) | 9 days ago 54% | 4 days ago 56% |
| BollingerBands ODDS (%) | 1 day ago 45% | 1 day ago 47% |
| Aroon ODDS (%) | 1 day ago 66% | 1 day ago 46% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BSX’s FA Score shows that 0 FA rating(s) are green while MDT’s FA Score has 1 green FA rating(s).
- BSX’s FA Score: 0 green, 5 red.
- MDT’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BSX’s TA Score shows that 4 TA indicator(s) are bullish while MDT’s TA Score has 6 bullish TA indicator(s).
- BSX’s TA Score: 4 bullish, 4 bearish.
- MDT’s TA Score: 6 bullish, 5 bearish.
Price Growth
BSX (@Medical/Nursing Services) experienced а +4.24% price change this week, while MDT (@Medical/Nursing Services) price change was +1.19% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -1.50%. For the same industry, the average monthly price growth was -10.64%, and the average quarterly price growth was -10.25%.
Reported Earning Dates
BSX is expected to report earnings on Oct 28, 2026.
MDT is expected to report earnings on Nov 17, 2026.
Industries' Descriptions
@Medical/Nursing Services (-1.50% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
Advertisement
BSX and
Correlation & Price change
A.I.dvisor indicates that over the last year, BSX has been closely correlated with ISRG. These tickers have moved in lockstep 71% of the time. This A.I.-generated data suggests there is a high statistical probability that if BSX jumps, then ISRG could also see price increases.
| Ticker / NAME | Correlation To BSX | 1D Price Change % | ||
|---|---|---|---|---|
| BSX | 100% | +3.37% | ||
| ISRG - BSX | 71% Closely correlated | +3.67% | ||
| MMSI - BSX | 56% Loosely correlated | +2.78% | ||
| ALC - BSX | 49% Loosely correlated | +4.75% | ||
| MDT - BSX | 46% Loosely correlated | +3.83% | ||
| NTRA - BSX | 45% Loosely correlated | -2.91% | ||
More | ||||
MDT and
Correlation & Price change
A.I.dvisor indicates that over the last year, MDT has been loosely correlated with SYK. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if MDT jumps, then SYK could also see price increases.